Salix Pharmaceuticals, Ltd. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Valeant Pharmaceuticals International, Inc.

NEW YORK, Feb. 23, 2015 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") SLXP breached its fiduciary duty to its shareholders in agreeing to sell Salix to Valeant Pharmaceuticals International, Inc. VRX VRX.

Under the terms of the agreement, Salix shareholders will receive $158.00 in cash for each share they own.  The investigation is focused on the potential unfairness of the price to Salix shareholders and the process by which the Salix Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Salix stockholder, with no obligation or cost to you, please contact U. Seth Ottensoser at:

(877) 779-1414
or
Ottensoser@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients.  It has been named to The National Law Journal's "Plaintiffs' Hot List" in each of the last twelve years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP.  The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.  The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/salix-pharmaceuticals-ltd-shareholder-alert-bernstein-liebhard-llp-announces-investigation-of-acquisition-by-valeant-pharmaceuticals-international-inc-300039779.html

SOURCE Bernstein Liebhard LLP